Company Description
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia.
The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues.
Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.
It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens.
The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021.
The company was founded in 2003 and is based in Hamilton, Bermuda.
| Country | Bermuda |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Thomas Meyer |
Contact Details
Address: Clarendon House, 2 Church Street Hamilton, HM 11 Bermuda | |
| Phone | 441 295 5950 |
| Website | altamiratherapeutics.com |
Stock Details
| Ticker Symbol | CYTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001601936 |
| CUSIP Number | G0360L100 |
| ISIN Number | BMG0360L1349 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas Meyer Ph.D. | Founder, President, Chairman, Chief Executive Officer and MD |
| Marcel Gremaud CPA | Chief Financial Officer |
| Dr. Covadonga Paneda | Chief Operating Officer |
| Dr. Samuel A. Wickline M.D. | Chief Scientific Adviser |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 4, 2024 | 6-K | Report of foreign issuer |
| Sep 24, 2024 | 6-K | Report of foreign issuer |
| Sep 19, 2024 | 6-K | Report of foreign issuer |
| Sep 18, 2024 | 424B4 | Prospectus |
| Sep 17, 2024 | EFFECT | Notice of Effectiveness |
| Sep 16, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Sep 16, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Aug 28, 2024 | UPLOAD | Filing |
| Aug 22, 2024 | F-1 | Registration statement for certain foreign private issuers |